荧光膀胱镜引导TUR-bt术疗效的荟萃分析  

Effects of fluorescence- guided TUR- bt on nonmuscle invasive bladder cancer: a meta- analysis

作　　者：王伟[1] 刘光明[1] 马洪顺[1] 郝晓明[1] 徐磊[1] 

机构地区：[1]天津医科大学一中心临床学院/天津市第一中心医院泌尿外科,天津300192

出　　处：《河南医学研究》2015年第3期17-20,共4页Henan Medical Research

摘　　要：目的：系统评价荧光膀胱镜引导经尿道膀胱肿瘤切除术（transurethral resection of bladder tumor，TUR －bt）治疗非肌层浸润性膀胱癌（nonmuscle invasive bladder cancer，NMIBC）的疗效。方法在国内外数据库中，检索15 a 内对比荧光膀胱镜和比普通膀胱镜辅助 TUR －BT 术疗效的随机对照研究（randomized controlled trial，RCT）。按纳入和排除标准选择文献、提取资料；采用 RevMan5．2软件进行荟萃分析。结果共纳入15篇随机对照试验，共2718例患者。分析结果显示，荧光膀胱镜辅助 TUR －bt 术治疗 NMIBC 后，肿瘤1年复发率（RR ＝0．71，95％ CI 0．58～0．87）、2年复发率（RR ＝0．60，95％ CI 0．50～0．73）差异均有统计学意义；术后远期肿瘤进展率（RR ＝0．81，95％ CI 0．62～1．13）差异无统计学意义。结论荧光膀胱镜引导 TUR －bt 可降低肿瘤复发率，但不能降低其进展为肌层浸润性膀胱癌的发生率。Objective To evaluate the outcome of fluorescence cystoscopy -guided transurethral resection of bladder tumor in the treatment of non -muscle invasive bladder cancer.Methods The 15 years’randomized controlled trials on fluorescence cystoscopy versus conventional cystoscopy -guided TUR -bt in the domestic and international databases were reviewed,materials were selected according to inclusion and exclusion criterias and informations were extracted.RevMan 5.2 software was used to conduct a meta -analysis.Results A total of 15 randomized controlled trials,a total of 2 718 cases of patients were included. 1 and 2 -year recurrence rates of fluorescence cystoscopy -guided TUR -bt treatment group were 0.71 （RR =0.71,95% CI 0.58 ～0.87）and 0.60 （RR =0.60,95% CI 0.50 ～0.73 ）,and the difference was statistically significant.But long -term postoperative tumor progression rate （RR =0.81,95% CI 0.62 ～1.13）was not statistically different.Conclusion The fluores-cence cystoscopy -guided TUR -bt can reduce the rate of tumor recurrence,but it does not reduce the incidence of progression to muscle invasive bladder cancer.

关 键 词：荧光膀胱镜 非肌层浸润性膀胱癌 META 分析 

分 类 号：R737.14[医药卫生—肿瘤]